Multiple Myeloma: « 20 » and « 100 » Ratios Cut-off applicable to Sebia FLC assays
The « 20 » and « 100 » Ratios Cut-off can be used in routine with Sebia FLC assays for high-risk smoldering multiple myeloma stratification and for assessing progression to active multiple myeloma or amyloidosis.
Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies – MDPI – 2019
This special Issue related to newborn screening for Sickle Cell disease and other hemoglobinopathies tried to cover the most widely faced challenges in the field of newborn screening for SCD.
Experience and recommendations of a Major Cancer Center to use HYDRASHIFT daratumumab
Immunotherapies for Multiple Myeloma, like the monoclonal antibody daratumumab, can create false positive IgG Kappa bands on Immunofixation gels. This paper describes best practice guidelines for using the Hydrashift assay to remove daratumumab interference from Immunofixation gels.
von Willebrand Factor and COVID-19
Correlation of von Willebrand factor with the severity of COVID-9 progression.
HYDRASHIFT avoids monoclonal antibody interference on IMMUNOFIXATION
The HYDRASHIFT portfolio include IVD test to mitigate interferences seen in immunofixation result for patient treated with isatuximab or daratumumab.
Pitfalls and ceveats of A1AT diagnosis
Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians.
Evaluation of Sebia’s isoelectrofocusing kit for A1AT
Evaluation of Sebia’s isoelectrofocusing kit for A1AT with HYDRASYS.
International standardization of CDT measurement
IFCC CDT-Working Group standardized the CDT measurement.